Peplin

About:

Peplin is a specialty pharmaceutical company focused on advancing and commercializing medical dermatology products.

Top Investors: New Enterprise Associates, MPM Capital, GBS Ventures, BioScience Managers Limited, Orbis Investment Management

Description:

Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.

Total Funding Amount:

$24M

Headquarters Location:

Emeryville, California, United States

Founded Date:

1998-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2014-08-13

IPO Status:

Private

Industries: